Form 8-K - Current report:
SEC Accession No. 0001641172-25-014445
Filing Date
2025-06-10
Accepted
2025-06-10 08:30:38
Documents
15
Period of Report
2025-06-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 47147
2 EX-99.1 ex99-1.htm EX-99.1 25814
3 GRAPHIC ex99-1_001.jpg GRAPHIC 8928
  Complete submission text file 0001641172-25-014445.txt   320977

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE asbp-20250610.xsd EX-101.SCH 3800
5 XBRL DEFINITION FILE asbp-20250610_def.xml EX-101.DEF 28286
6 XBRL LABEL FILE asbp-20250610_lab.xml EX-101.LAB 37863
7 XBRL PRESENTATION FILE asbp-20250610_pre.xml EX-101.PRE 26498
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 7374
Mailing Address 194 CANDELARO DRIVE, #233 HUMACAO PR 00791
Business Address 194 CANDELARO DRIVE, #233 HUMACAO PR 00791 561-704-8527
Aspire Biopharma Holdings, Inc. (Filer) CIK: 0001847345 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41293 | Film No.: 251036002
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)